gevokizumab experimental monoclonal antibody developed xoma corporation allosteric modulating properties gevokizumab binds beta proinflammatory cytokine downmodulates cellular signaling events produce inflammation beta implicated cardiovascular conditions lung cancer autoinflammatory diseases august xoma corporation licensed global commercial rights gevokizumab novartis license agreement novartis worldwide rights gevokizumab solely responsible development commercialization antibodies products containing antibodies arising gevokizumab xoma received approximately million upfront payment novartis repaid entirety approximately million debt owed xoma les laboratoires servier xoma eligible receive million development regulatory commercial milestones plus tiered highsingle middoubledigit royalties net sales gevokizumab immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikigevokizumab